PubRank

David R Adams

Author PubWeight™ 60.36‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003 3.43
2 Interstitial granulomatous drug reaction to anakinra. J Am Acad Dermatol 2008 1.85
3 A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell 2013 1.75
4 Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKs. Biochem J 2008 1.62
5 Sterile inflammation associated with transradial catheterization and hydrophilic sheaths. Catheter Cardiovasc Interv 2003 1.52
6 Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5. Biochem J 2006 1.46
7 Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for insulin-like growth factor I-mediated regulation of focal adhesion kinase. J Biol Chem 2009 1.33
8 DNA variations in oculocutaneous albinism: an updated mutation list and current outstanding issues in molecular diagnostics. Hum Mutat 2013 1.25
9 Eczema herpeticum: a dermatologic emergency. Dermatol Nurs 2002 1.25
10 An analysis of exome sequencing for diagnostic testing of the genes associated with muscle disease and spastic paraplegia. Hum Mutat 2012 1.25
11 Analysis of group differences in processing speed: Brinley plots, Q-Q plots, and other conspiracies. Psychon Bull Rev 2003 1.18
12 The National Institutes of Health undiagnosed diseases program. Curr Opin Pediatr 2014 1.14
13 Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays. Biochem J 2007 1.10
14 Synthesis and biological activity of some structural modifications of pancratistatin. Bioorg Med Chem Lett 2004 1.09
15 Novel anti-infective compounds from marine bacteria. Mar Drugs 2010 1.08
16 MEK1 binds directly to betaarrestin1, influencing both its phosphorylation by ERK and the timing of its isoprenaline-stimulated internalization. J Biol Chem 2009 1.02
17 Nitisinone improves eye and skin pigmentation defects in a mouse model of oculocutaneous albinism. J Clin Invest 2011 0.99
18 Extracellular loop 2 of the free fatty acid receptor 2 mediates allosterism of a phenylacetamide ago-allosteric modulator. Mol Pharmacol 2011 0.99
19 1H NMR structural and functional characterisation of a cAMP-specific phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts PDE4D5 interaction with the signalling scaffold proteins, beta-arrestin and RACK1. Cell Signal 2007 0.95
20 Atypical patterns of inheritance. Semin Pediatr Neurol 2007 0.95
21 Biofilm-specific cross-species induction of antimicrobial compounds in bacilli. Appl Environ Microbiol 2003 0.94
22 The development of a marine natural product-based antifouling paint. Biofouling 2003 0.93
23 High-content screening of feeder-free human embryonic stem cells to identify pro-survival small molecules. Biochem J 2010 0.93
24 Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. Bioorg Med Chem Lett 2008 0.92
25 Selective SUMO modification of cAMP-specific phosphodiesterase-4D5 (PDE4D5) regulates the functional consequences of phosphorylation by PKA and ERK. Biochem J 2010 0.91
26 Elucidation of a structural basis for the inhibitor-driven, p62 (SQSTM1)-dependent intracellular redistribution of cAMP phosphodiesterase-4A4 (PDE4A4). J Med Chem 2011 0.90
27 RACK1 to the future--a historical perspective. Cell Commun Signal 2013 0.90
28 Spa contact dermatitis. Dermatitis 2008 0.89
29 Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process. Cell Signal 2003 0.88
30 Direct interaction between scaffolding proteins RACK1 and 14-3-3ζ regulates brain-derived neurotrophic factor (BDNF) transcription. J Biol Chem 2011 0.88
31 Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB J 2012 0.88
32 A scanning peptide array approach uncovers association sites within the JNK/beta arrestin signalling complex. FEBS Lett 2009 0.88
33 Free sialic acid storage disease without sialuria. Ann Neurol 2009 0.87
34 Recombination mapping using Boolean logic and high-density SNP genotyping for exome sequence filtering. Mol Genet Metab 2011 0.86
35 Comparative effects of single-mode vs. duration-matched concurrent exercise training on body composition, low-grade inflammation, and glucose regulation in sedentary, overweight, middle-aged men. Appl Physiol Nutr Metab 2013 0.85
36 Chemoenzymatic synthesis of inositols, conduritols, and cyclitol analogues. Chem Rev 2011 0.83
37 p62 (SQSTM1) and cyclic AMP phosphodiesterase-4A4 (PDE4A4) locate to a novel, reversible protein aggregate with links to autophagy and proteasome degradation pathways. Cell Signal 2010 0.83
38 Putting the lid on phosphodiesterase 4. Nat Biotechnol 2010 0.83
39 Allopurinol hypersensitivity syndrome. J Drugs Dermatol 2002 0.83
40 Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene. Biochem J 2004 0.82
41 JM47, a cyclic tetrapeptide HC-toxin analogue from a marine Fusarium species. Phytochemistry 2002 0.81
42 Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity. Bioorg Med Chem 2012 0.80
43 Interaction of caspase-3 with the cyclic GMP binding cyclic GMP specific phosphodiesterase (PDE5a1). Eur J Biochem 2003 0.80
44 Genome-scale sequencing to identify genes involved in Mendelian disorders. Curr Protoc Hum Genet 2013 0.80
45 Phosphodiesterase inhibitors. Part 1: Synthesis and structure-activity relationships of pyrazolopyridine-pyridazinone PDE inhibitors developed from ibudilast. Bioorg Med Chem Lett 2011 0.79
46 Serine phosphorylation of the insulin-like growth factor I (IGF-1) receptor C-terminal tail restrains kinase activity and cell growth. J Biol Chem 2012 0.79
47 Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4). Biochem Pharmacol 2013 0.79
48 Stinging nettle dermatitis. Am J Contact Dermat 2003 0.79
49 Identification and characterization of small-molecule ligands that maintain pluripotency of human embryonic stem cells. Biochem Soc Trans 2010 0.77
50 Concise routes to pyrazolo[1,5-a]pyridin-3-yl pyridazin-3-ones. Org Biomol Chem 2007 0.77
51 The Hershey access clinic: a model for improving patient access. J Am Acad Dermatol 2007 0.77
52 Synthesis of buprenorphine from oripavine via N-demethylation of oripavine quaternary salts. J Org Chem 2011 0.77
53 Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib. J Drugs Dermatol 2011 0.77
54 Irritant contact dermatitis to the brown marmorated stink bug, Halyomorpha halys. Dermatitis 2012 0.77
55 Phosphodiesterase inhibitors. Part 5: hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration. Bioorg Med Chem Lett 2012 0.76
56 Phosphodiesterase inhibitors. Part 2: design, synthesis, and structure-activity relationships of dual PDE3/4-inhibitory pyrazolo[1,5-a]pyridines with anti-inflammatory and bronchodilatory activity. Bioorg Med Chem Lett 2011 0.76
57 Diffuse clusters of vesicles on the face and extremities of a 10-month-old girl. Pediatr Dermatol 2010 0.76
58 Successful use of adalimumab in treating cutaneous metastatic Crohn's disease: report of a case. Inflamm Bowel Dis 2009 0.76
59 Erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) blocks differentiation and maintains the expression of pluripotency markers in human embryonic stem cells. Biochem J 2010 0.76
60 Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones. Bioorg Med Chem Lett 2012 0.76
61 Insect repellents and mosquito bites. N Engl J Med 2002 0.75
62 A hitherto unnamed dermatologic entity with clinical features of both psoriasis and eczema. Skinmed 2006 0.75
63 Etanercept and warts. J Drugs Dermatol 2004 0.75
64 Fine wrinkling of the thighs and axillae--quiz case. Middermal elastolysis. Arch Dermatol 2010 0.75
65 What's eating you? Oak leaf itch mite (Pyemotes herfsi). Cutis 2011 0.75
66 Persistent allergic contact dermatitis to plastic toilet seats. Pediatr Dermatol 2011 0.75
67 Methotrexate sodium-associated UV reactivation in a patient with acute lymphoblastic leukemia. Cutis 2012 0.75
68 JAAD grand rounds. Increased fragility and bulla formation on the dorsal surface of the hand. J Am Acad Dermatol 2012 0.75
69 Cutaneous cryptococcus in an elderly woman with chronic essential dermatitis. Cutis 2006 0.75
70 JAAD grand rounds. Erythematous macules and crusted erosions in sun-exposed areas. J Am Acad Dermatol 2012 0.75
71 Several generations of chemoenzymatic synthesis of oseltamivir (Tamiflu): evolution of strategy, quest for a process-quality synthesis, and evaluation of efficiency metrics. J Org Chem 2011 0.75